Over the past 20 years, cancer therapies that target particular genetic abnormalities in tumors have completely changed the way that treatments could be delivered. Targeted therapies improve quality of life and survival, but relapse is frequent because new tumor cells have developed that are resistant to the therapy. A protein called APOBEC3A that may be a promising target has been identified as the mechanism by which lung tumors may develop drug resistance over time. The findings might aid in the creation of fresh treatments for tumor resistance to particular cancer therapies.
Researchers pinpoint protein tied to drug resistance in patients with lung cancer
